Entero Therapeutics GRDX

Entero Therapeutics Appoints Richard Paolone as CEO

Form
8-K
Filed
Period
Importance
Major
Document
8-K
Exhibit 99.1
Press release
  • Reports an executive or board change (5.02)
  • Makes a Regulation FD disclosure (7.01)

Not explained yet; the original is on EDGAR.

Get an email when Entero Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (4931) and public float under $300M, nearest public float first, as each company reports it on its annual report cover.